357 related articles for article (PubMed ID: 29760419)
1. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
2. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Masuyama H; Nakamura K; Nobumoto E; Hiramatsu Y
Int J Oncol; 2016 Sep; 49(3):1211-20. PubMed ID: 27572875
[TBL] [Abstract][Full Text] [Related]
4. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
5. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
6. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
7. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
11. AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2019 Feb; 39(2):609-617. PubMed ID: 30711936
[TBL] [Abstract][Full Text] [Related]
12. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
13. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation of crocetin into poly (lactic-co-glycolic acid) nanoparticles overcomes drug resistance in human ovarian cisplatin-resistant carcinoma cell line (A2780-RCIS).
Neyshaburinezhad N; Kalalinia F; Hashemi M
Mol Biol Rep; 2019 Dec; 46(6):6525-6532. PubMed ID: 31646427
[TBL] [Abstract][Full Text] [Related]
15. [Reversal of multi-drug resistance in ovarian cancer cell by RNA interference].
Lou JY; Peng ZL; Zheng Y; Wang H; He B; Wang HJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):413-6. PubMed ID: 16831368
[TBL] [Abstract][Full Text] [Related]
16. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
Duan Z; Brakora KA; Seiden MV
Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
[TBL] [Abstract][Full Text] [Related]
18. Reversal of Ovarian Cancer Multidrug Resistance by a Combination of LAH4-L1-siMDR1 Nanocomplexes with Chemotherapeutics.
Guo N; Gao C; Liu J; Li J; Liu N; Hao Y; Chen L; Zhang X
Mol Pharm; 2018 May; 15(5):1853-1861. PubMed ID: 29621396
[TBL] [Abstract][Full Text] [Related]
19. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
20. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]